Chronic Lymphocytic Leukaemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Malignant Melanoma, Mantle Cell Lymphoma, Non-small Cell Lung Cancer (NSCLC), Small Lymphocytic Lymphoma
Conditions
Keywords
ROR1 positive cancers, Bispecific T cell engagers
Brief summary
NVG-111 is a bispecific antibody drug, having two arms, one arm attaches to a substance on cancer cells called ROR1, the other arm attaches to the body's immune cells directing them to kill the cancer cells. This is the first clinical trial of the drug NVG-111, and will include patients with certain types of cancer including chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) mantle cell lymphoma (MCL), follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL) in Group A. Subjects with solid tumours, focusing initially on stage IV non-small cell lung cancer (NSCLC) or malignant melanoma.
Detailed description
Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) is a protein which is expressed at high levels on many types of cancers but is absent or expressed at low levels in normal adult organs. NVG-111 is a bispecific antibody T cell engager, comprising tandem single chain variable fragments (scFv), one arm binding to ROR1 on cancer cells, the other to cell surface CD3 on lymphocytes. Dual binding of NVG-111 causes MHC-independent immunological synapse formation, releasing perforins, granzyme B and cytokines, resulting in targeted killing of the cancer cells. This is a Phase 1 first in human study to assess the safety, pharmacokinetics and efficacy of NVG-111 in patients with subjects with relapsed/refractory ROR1+ malignancies. A range of doses will be studied in sequential cohorts to understand safety, pharmacokinetics and pharmacodynamics of the drug and establish the recommended phase 2 dose (RP2D). At each dose level, patients will receive 3 cycles of NVG-111 by continuous intravenous infusion, each cycle consists of 21 days treatment. Additional cycles may be given depending on the response seen. All patients will have a safety follow up visit 4 weeks after completion of treatment with NVG-111, and will then enter long term follow up for up to two years to evaluate the duration of efficacy.
Interventions
DRUGNVG-111
Open label, continuous iv infusion, escalating doses of NVG-111 for minimum 3 cycles
Sponsors
NovalGen Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Personally signed informed consent document. * Male or female, age ≥18 years. * Relapsed or refractory ROR1+ malignancies * ECOG performance status ≤2. * Adequate organ function. * Bilirubin ≤1.5 x ULN (unless Gilbert's syndrome). * AST and ALT ≤2.5 x ULN (if no hepatic CLL or MCL), or AST and ALT ≤5 x ULN (if hepatic CLL or MCL). * APTT and PT ≤1.5 x ULN. * ANC ≥0.5 x 10\^9 /L (without growth factors) and platelets ≥ 30 x 10\^9 /L (without transfusion). * Serum creatinine ≤2 x ULN. * Estimated creatinine clearance ≥30 mL/min. * In females of childbearing potential, a negative serum pregnancy test. * For both males and females, willingness to use adequate contraception. * Willingness and ability to comply with study procedures.
Exclusion criteria
* Richter's transformation. * CNS or leptomeningeal active disease. * High tumour bulk as defined in the protocol. * Allogeneic or autologous organ transplant within prior 6 months. * Uncontrolled autoimmune haemolytic anaemia or idiopathic thrombocytopenic purpura within 8 weeks of screening. * Clinically significant neurological disease. * Clinically significant cardiovascular disease or ECG abnormalities. * Severe chronic lung disease. * Positive test at Screening for HIV, hepatitis B or hepatitis C infection. * Any other concurrent cancer or cancer treatments. * Uncontrolled ongoing infection * Recent major surgery * Concurrent participation in another clinical trial, or experimental therapy within 5 half-lives of Screening * Pregnant or currently breastfeeding. * Any other medical condition that in the opinion of the investigator contraindicates participation in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of treatment-emergent adverse events (TEAEs) | Up to 10 months | Safety parameter assessed by: type, frequency, severity and treatment-relatedness of AEs following commencement of dosing |
| Number of serious adverse events (SAEs) | Up to 10 months | Safety parameter defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent disability/incapacity, is a congenital anomaly/birth defect, or is medically significant/important |
| Number of adverse events of special interest (AESI) | Up to 10 months | Safety parameter: specific protocol-defined AEs of Grade \>=3 |
| Number of dose limiting toxicities (DLTs) | Up to 28 days | Safety parameter assessed by protocol-defined adverse events |
| Laboratory safety abnormalities | Up to 10 months | Safety parameter assessed by absolute values and change from baseline in laboratory safety assessments |
| Vital sign abnormalities | Up to 10 months | Safety parameter assessed by absolute values and change from baseline in vital signs |
| ECG abnormalities | Up to 10 months | Safety parameter assessed by absolute value and change from baseline in ECG intervals including QTcF |
| Changes from baseline in ECOG | Up to 10 months | Safety parameter assessed by change from baseline in ECOG performance status |
Countries
United Kingdom
Contacts
Primary ContactAmit C Nathwani, MBChB, FRCP, FRCPath, PhD
Outcome results
None listed